 |
Prospector
Profile
1129-06
|
| |
| ZIOPHARM Oncology, Inc. |
NAICS |
541710 |
| 1180 Avenue of the Americas, 19th Floor
New York, NY 10036 |
Description |
Biotechnology |
| (646) 214-0700 |
Employees |
28 |
| http://www.ziopharm.com/ |
Revenue |
(mil) |
0.0000 |
| |
Income |
(mil) |
-17.8560 |
| |
Assets |
(mil) |
29.5120 |
| |
Liability |
(mil) |
2.9790 |
| |
(for the year ended 2006-12-31) |
| |
|
Category:
Loss/Deficit
|
| |
|
Event:
ZIOPHARM Oncology, Inc. had a net loss of $7,323,366 for the three months ended September 30, 2007, much higher than the $3,454,502 net loss reported during the three months ended September 30, 2006. For the nine months ended September 30, 2007, the Company had a $18,909,253 net loss, much lower than the $12,038,252 net loss reported during the nine months ended September 30, 2006. As a result of its recurring losses, the Company has an accumulated deficit of $52,130,528 as of September 30, 2007.
|
| |
|
Intellectual Property:
On August 24, 2004, the Company entered into a Patent and Technology License Agreement with The Board of Regents of the University of Texas System, under which the Company was granted an exclusive, worldwide license to rights for the manufacture and commercialization of two classes of organic arsenicals for human and animal use, one of which includes ZIO-101. In October 2004, the Company received a notice of allowance for U.S. Patent Application No. 10/337969, entitled “S-dimethylarsino-thiosuccinic acid S-dimethylarsino-2-thiobenzoic acid S-(simethylarsino) glutathione as treatments for cancer.” The patent was granted on June 28, 2005 as U.S. Patent No. 6,911,471. The patent application claims both therapeutic uses and pharmaceutical compositions containing a novel class of organic arsenicals, including ZIO-101, for the treatment of cancer. In February 2006, the Company announced that a second organic arsenic case has been issued under U.S. Patent No. 6,995,188. This patent provides further coverage of cancer treatment using organic arsenic, including ZIO-101, in combination with other agents or therapies. In addition, there were seven patents related to ZIO-101 that issued in various foreign countries in 2006. On October 15, 2004, the Company entered into a license agreement with DEKK-Tec, Inc., pursuant to which it was granted an exclusive, worldwide license to the second of its lead product candidates, ZIO-201. On December 22, 2004, the Company entered into an Option Agreement with Southern Research Institute (SRI), pursuant to which it was granted an exclusive option to obtain an exclusive license to SRI’s interest in certain intellectual property, including exclusive rights related to certain isophosphoramide mustard analogs. [SEC Filing 10-KSB 02-13-07]
|
| |
|
Description:
The Company engages in the development and commercialization of a portfolio of in-licensed cancer drugs.
|
| |
|
Officers:
Jonathan Lewis (CEO & Dir.); Richard Bagley (Pres., COO, CFO, Treas. & Dir.); Murray Brennan (Dir.); James Cannon (Dir.); Timothy McInerney (Dir.); Wyche Fowler, Jr. (Dir.); Gary S. Fragin (Dir.); Michael Weiser (Dir.)
|
| |
|
Auditor:
Vitale Caturano & Company Ltd.
|
| |
|
Securities:
Common Stock-Symbol ZIOP; NasdaqCM;
21,220,614 common shares outstanding as of November 2, 2007.
|
| |
| |
| |
| return to main page |
|
|
